VRI launches probiotics into pharmacies

VRI BioMedical announced today that its probiotics range for the treatment of irritable bowel syndrome, diarrhoea and general intestinal health, is due to hit pharmacy shelves.

The probiotics – marketed as ‘proTract’ - are a strain of Lactobacillus Fermentum, shown to have a mucosal immune boosting action.

Unlike other probiotics, which must be refrigerated, the microorganisms are hardy enough to be freeze-dried and encapsulated.

“The proTract range is a result of research and clinical trial data which has shown particular probiotics strains to be effective in the treatment of a range of gut related conditions,” said VRI managing director Dr Peter French.

“Until now there has been no effective treatment of IBS, with a focus on symptoms such as diarrhoea or bloating, but no attempt to address the underlying causes.”

VRI BioMedical last week appointed Prof Ron Penny, AO, and Professor Terry Bolin to the company’s Scientific and Medical Advisory Board.